Advanced search
Start date
Betweenand


Pharmaceutical care on hypertension: clinical, economic and social impact

Full text
Author(s):
Thaís Rodrigues Penaforte
Total Authors: 1
Document type: Doctoral Thesis
Press: Ribeirão Preto.
Institution: Universidade de São Paulo (USP). Faculdade de Ciências Farmacêuticas de Ribeirão Preto (PCARP/BC)
Defense date:
Examining board members:
Osvaldo de Freitas; Maria Suely Nogueira; Leonardo Régis Leira Pereira; Ricardo Radighieri Rascado; Julieta Mieko Ueta
Advisor: Osvaldo de Freitas
Abstract

Pharmacists are considered the most qualified professionals for clinical and humanistic drug therapy management. The practice in agreement with the pharmaceutical care philosophy provides an exercise which the professional takes responsibility for all the patient needs and get a commitment in this regard. This type of care describes a method centered on reflective and relational responsibility for new knowledge and practices. As the management and experience of hypertension involve several dimensions, the differentiated assistance of pharmaceutical care provides an alternative to construct a new heath reality. Aiming to investigate the clinical, humanistic and economic aspects, a pharmaceutical care model was implemented in two health units (UBDS-CSE / Sumarezinho and UBS Dom Mielle) in Ribeirão Preto,SP. The service followed 104 patients who participated of 12 pharmaceutical consultations and multiprofessional educational actions. The final analysis showed a slight reduction on the body mass index (BMI) of 0.82 ± 1.11. The hemodynamic data revealed a statistically significant reduction in blood pressure, of 18.18 ± 12.45 mm Hg in systolic blood pressure and 7.18 ± 4.28 mmHg in diastolic blood pressure. The baseline Framingham coronary heart disease (CHD) score was 14.65% and was reduced to 10.90%. The drug therapy profile showed an average of 2 antihypertensive medications per patient with the predominant class of thiazide diuretics, ACE inhibitors and beta blockers. Medication adherence was one aspect of greatest response to pharmaceutical care. At the baseline 54.81% of participants were classified as non-compliant and at the final all patients maintained the adherence profile for at least 3 months. The social survey involved aspects of quality of life (SF-36) and users satisfaction with pharmaceutical services. There was a significant improvement in all eight SF-36 components, with emphasis on the physical aspects that showed the best performance. Pharmaceutical services were highly rated by the users with an average of 4.61 ± 0.73 pts. The best rated item was the question 12 (orientation of the pharmacist) and the lowest evaluation was to question 13 (pharmacy services). The economic evaluation followed the concept of expected value, defined as the expected cost of hospitalization for cardiovascular disease. Pharmaceutical care has shown a 3.77% reduction on CHD risk that matches a cost of R$ 67.82 per patient. Considering the full time pharmacist work, this economy may reach R$ 26,042.88 per month. Based on these results, we conclude that pharmaceutical care improved blood pressure control, with positively influence on clinical aspects, quality of life and prove be economically efficient. (AU)

FAPESP's process: 07/06514-5 - Pharmaceutical Care on Hypertension : clinical impact, economic and social
Grantee:Thais Rodrigues Penaforte
Support type: Scholarships in Brazil - Doctorate